Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Prior Bad Conduct By Pharma Companies Could Be ‘Plus Factor’ In Merger Review

Jun 16 2022

• By Brenda Sandburg

M&A image — Past anticompetitive behaviour of pharma companies could influence FTC merger analysis • Source: Shutterstock

Related Content

FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal

Jul 02 2018

Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme

Mar 17 2021

Restasis Patent Review Back On Track As Federal Circuit Quashes Mohawk Tribe's Sovereign Immunity Claim

Jul 23 2018

Merger Enforcement: FTC And Justice Department Casting Wide Net In Considering Changes

Jan 19 2022

FTC Narrowly Okays AbbVie/Allergan Merger As Dissenter Slams Divestitures To AstraZeneca, Nestlé

May 07 2020

Unlikely Foe Gets AbbVie To Alter Humira Marketing Practices In California

Aug 07 2020

Allergan Loses Another Battle, But War To Block Restasis Generics Continues

Jan 19 2018

Related Companies

AbbVie Inc.

Allergan plc

Teva Pharmaceuticals USA Inc.

Boehringer Ingelheim GmbH

Additional Topics

United States M & A Enforcement Legal Issues Commercial Policy BioPharmaceutical

More from Compliance

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.